Merck KGaA, MilliporeSigma make investments in the US and China manufacturing
Merck KGaA announced a pair of manufacturing expansions in the US and China that aim to increase the production of testing materials and cell cultures.
The German drugmaker last week announced that it expects to expand its manufacturing capacity for producing highly-purified reagents used for quality control and testing at its site in Nantong, China. It plans to invest €70 million ($78.1 million) in building a new reagent production plant there that will cover 40,000 square meters or about 430,000 square feet. Once completed, the facility will increase its reagent output by around several thousand tons.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.